Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Rivaroxaban 10-mg Tablet Formulations in Healthy Thai Volunteers (Fasting)
TCTR20220720009Phase 1Completed
- Sponsor
- Sun Pharma
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of rivaroxaban in venous thromboembolism (VTE) and Atrial fibrillation (AFib) (2 arms), sponsored by Sun Pharma. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Started Aug 2023; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on TCTR20220720009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220720009.